期刊
SCIENCE
卷 370, 期 6520, 页码 1058-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abd4250
关键词
-
资金
- National Institutes of Health [NIH AI121394, AI139538]
- Burroughs Wellcome Fund
- Fast Grant award
- Division of Intramural Research, NIAID, NIH
- Executive Committee on Research, MGH
- MassCPR
- National Institutes of Health
- Department of Defense [AI138318, AR070253, W81XWH-16-1-0464]
- NIH/NIAID
- Pemberton-Trinity Fellowship
- Sir Henry Wellcome Fellowship [201387/Z/16/Z]
- NSF Graduate Research Fellowship Program
- Mark and Lisa Schwartz Foundation
- Massachusetts Consortium for Pathogen Readiness
- Ragon Institute of MGH, MIT and Harvard
- VoVRN
- Wellcome Trust [201387/Z/16/Z] Funding Source: Wellcome Trust
Understanding humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for improving diagnostics, therapeutics, and vaccines. Deep serological profiling of 232 coronavirus disease 2019 (COVID-19) patients and 190 pre-COVID-19 era controls using VirScan revealed more than 800 epitopes in the SARS-CoV-2 proteome, including 10 epitopes likely recognized by neutralizing antibodies. Preexisting antibodies in controls recognized SARS-CoV-2 ORF1, whereas only COVID-19 patient antibodies primarily recognized spike protein and nucleoprotein. A machine learning model trained on VirScan data predicted SARS-CoV-2 exposure history with 99% sensitivity and 98% specificity; a rapid Luminex-based diagnostic was developed from the most discriminatory SARS-CoV-2 peptides. Individuals with more severe COVID-19 exhibited stronger and broader SARS-CoV-2 responses, weaker antibody responses to prior infections, and higher incidence of cytomegalovirus and herpes simplex virus 1, possibly influenced by demographic covariates. Among hospitalized patients, males produce stronger SARS-CoV-2 antibody responses than females.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据